Previously, we demonstrated that MT218-MRMI targeting ELNP/miR-200c effectively reduced EDB-FN levels in the ECM of triple-negative breast cancer (TNBC), inhibiting tumor proliferation [21]. This evidence concerns the gene FN1 and neoplasm.